Industry

NewAmsterdam Pharma to Present at Upcoming Medical Conferences New Post-Hoc Analyses from Phase 2 ROSE Trial of Obicetrapib in Patients with Dyslipidemia

New post-hoc data accepted as late breaking abstracts at the 90th European Atherosclerosis Society (EAS) Congress and 2022 National Lipid Association (NLA) Scientific Sessions NAARDEN, Netherlands & MIAMI–(BUSINESS WIRE)–NewAmsterdam Pharma (NewAmsterdam), a clinical-stage company focused on the research and development of transformative oral therapies for metabolic diseases, today announced that it will present new post-hoc … [Read more…]

Pear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022

BOSTON–(BUSINESS WIRE)–Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it will host an inaugural virtual Investor Day on June 6, 2022, at 10:00 a.m. – 12:30 p.m. ET. Pear’s Investor Day will feature presentations by members of the management team. The company … [Read more…]

Schrödinger Announces Appointment of Arun Oberoi to Board of Directors

NEW YORK–(BUSINESS WIRE)–$SDGR—Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Arun Oberoi to its Board of Directors, effective May 17, 2022. Mr. Oberoi will serve as a member of the Audit Committee. “We are very pleased to welcome Arun to our … [Read more…]

Mevion Selected to Equip Proton Center in Southern China

LITTLETON, Mass.–(BUSINESS WIRE)–#ProtonTherapy—Mevion Medical Systems announced today that it has been selected to install a MEVION S250i Proton Therapy System® with HYPERSCAN® Pencil Beam Scanning (PBS) in a comprehensive hospital in Southern China. Proton therapy is a superior form of radiation therapy that can reduce the amount of unnecessary radiation exposure to surrounding healthy tissue … [Read more…]

Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC

FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CSTL–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing that DecisionDx-SCC can independently risk-stratify patients with cutaneous squamous cell carcinoma (SCC) and one or more risk factors according to their biologic risk of metastasis, consistent with findings in previous development … [Read more…]

Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting

– Pharmacokinetic profile supports potential for once-daily dosing in moderate-to-severe psoriasis – – Wide range of doses explore higher ranges of TYK2 inhibition in the clinic than reported by other agents – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a clinical-stage company that is working to design and develop breakthrough medicines through its powerful computational drug discovery engine, … [Read more…]

Alchemab Announces Publication of AntiBERTa, an Antibody-Specific Machine Learning Model with Multiple Applications

BOSTON & CAMBRIDGE, England–(BUSINESS WIRE)–Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, today announced the publication of research demonstrating the potential of AntiBERTa (Antibody-specific Bi-directional Encoder Representation and Transformers), a transformer neural network that reads the components of an antibody amino acid … [Read more…]

More than two in five Americans are more sensitive to stress than before the pandemic

LifeWorks Mental Health Index™ reveals 42 percent of Americans are feeling an increased sensitivity to stress CHICAGO–(BUSINESS WIRE)–LifeWorks, a leading provider of digital and in-person total wellbeing solutions, today released its monthly Mental Health Index™ that showed the 42 percent of Americans feeling more sensitive to stress have a mental health score more than 10 … [Read more…]

Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

— RP-L201 well-tolerated with durable CD18 expression for all patients in Phase 2 pivotal trial — — 100% overall survival in patients at one year after RP-L201 infusion based on Kaplan-Meier estimate — — All patients showed clinical reversal of disease course, including statistically significant reduction in all-cause hospitalizations and incidence of severe infections — … [Read more…]

Viral Conjunctivitis Drugs in Development Pipeline Guide 2022, by Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Viral Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering. The pipeline guide provides comprehensive information on the therapeutics under development for Viral Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route … [Read more…]